MedTrace Logo

CONcomitant eValuation of Epicor Left atRial Therapy for AF

NCT00519194 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2019-02-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the safety and efficacy of the Epicor LP Cardiac Ablation System for treating permanent atrial fibrillation during concomitant open chest and/or open heart surgery for one of more of the following procedures: mitral valve repair or replacement, aortic valve repair or replacement, tricuspid valve repair or replacement, coronary artery bypass surgery or patent foramen ovale (PFO closure).

Conditions

Interventions

DEVICE

Epicor LP Cardiac Ablation System

Surgical ablation of permanent AF during concomitant open chest and/or open heart surgery

PROCEDURE

Surgical ablation of permanent AF

Concomitant AF ablation during mitral valve surgery

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • Mark Groh, MD · Mission Hospitals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00519194 on ClinicalTrials.gov